science wire

« BACK

Pharmacology



Results 1 - 50 of 1997.
1 2 3 4 5 ... 40 Next »


Health - Pharmacology - 18.09.2020
Patches to detect when a viral disease is about to get worse
Xsensio, an EPFL spin-off, has just been awarded CHF 1.8 million in EU funding to adapt its Lab-on-Skin(TM) sensing patches so that they can detect when a viral illness like the flu or COVID-19 is about to get worse.

Health - Pharmacology - 17.09.2020
Talk of a "Twindemic"
No one knows what will happen next with COVID-19 still raging, but there is something you can do: Get your flu vaccination Even as the first wave of the pandemic still roils, fears are rising of a second crush of COVID-19 infections.

Health - Pharmacology - 16.09.2020
New £4m study to advance our understanding of severe coronavirus infection
The University of Liverpool is leading a major new international project to improve our understanding of severe coronavirus infection in humans, together with collaborators from the University of Oxford, Public Health England, the University of Bristol; A*STAR in Singapore; and King Fahd Medical City in Saudi Arabia.

Health - Pharmacology - 16.09.2020
RECOVERY COVID-19 phase 3 trial to evaluate Regeneron’s REGN-COV2 antibody cocktail
One of the world's largest efforts to find effective COVID-19 treatments will evaluate the impact of REGN-COV2 on mortality, hospital stays, and the need for ventilation. Regeneron Pharmaceuticals, Inc. and the University of Oxford today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world's largest randomised clinical trials of potential COVID-19 treatments, will evaluate Regeneron's investigational anti-viral antibody cocktail, REGN-COV2.

Health - Pharmacology - 16.09.2020
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
New Findings Recommend Patients with a Low HIV Viral Load Switch to Second-line Antiretroviral Therapy
HIV continues to be a major global health issue, having claimed almost 33 million lives.

Health - Pharmacology - 16.09.2020
Australia unprepared for over-the-counter medical cannabis sales
Australia unprepared for over-the-counter medical cannabis sales
Professor Iain McGregor from the Lambert Initiative says it is time for Australia to have a mature approach to consumer access to safe and effective cannabinoid products without a prescription.

Pharmacology - Health - 16.09.2020
Novartis Tafinlar + Mekinist demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM
COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1   Adjuvant treatment with

Pharmacology - Health - 14.09.2020
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD     The update includes the additional characterization of retinal vasculitis a

Pharmacology - Health - 11.09.2020
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta (ofatumumab) in newly diagnosed treatment-naļve adults with relapsing multiple sclerosis
New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naļve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to di

Health - Pharmacology - 11.09.2020
Global consortium launches new study into long-term effects of COVID-19
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC), based at Oxford University, in collaboration with Dr Janet Scott, of the MRC-University of Glasgow's Centre for Virus Research, has launched a longitudinal observational study to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19.

Health - Pharmacology - 09.09.2020
Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug
Waisman Biomanufacturing at the University of Wisconsin-Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection.

Health - Pharmacology - 08.09.2020
"These results are crucial for the future corona vaccination strategy"
Efforts are being made worldwide to combat the new coronavirus SARS-CoV-2. Vaccines and protective masks are of prime importance. Empa researcher Peter Wick, Head of the Particles-Biology Interactions Laboratory in St. Gallen, talks to Empa Quarterly about recent antibody studies, which are crucial for the development of a COVID-19 vaccine, and the next generation of textile protective materials that inactivate or even kill corona viruses.

Pharmacology - Health - 07.09.2020
Novartis post hoc analysis shows high-dose Enerzair Breezhaler reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhale

Pharmacology - 07.09.2020
CSL signs agreement with Australian Government for UQ vaccine supply
Global biotech company CSL Limited will supply the Australian Government with 51 million doses of The University of Queensland's COVID-19 vaccine candidate if it proves successful, under a heads of agreement announced today.

Health - Pharmacology - 07.09.2020
New global COVID-19 long term study launched
Researchers and clinicians in Glasgow will lead a global study into the long-term health impacts of COVID-19. The international, multi-site study is launched by ISARIC to measure prevalence and risk factors of long-term health and psychosocial consequences of COVID-19. The researchers are inviting hospitals and healthcare sites worldwide to join this new study.

Pharmacology - 07.09.2020
New digital tool to improve treatment for people with alcohol addiction
New digital tool to improve treatment for people with alcohol addiction
An online system to monitor symptoms and cravings will help combat heavy drinking and alcohol use disorders, which affect about a third of Australian men and a quarter of women at some point in their life.

Health - Pharmacology - 04.09.2020
HIIT the road to recovery for patients with heart disease
High intensity interval training (HIIT) can help heart patients with their recovery and is more effective than moderate-intensity continuous training in the short term, according to University of Queensland research.

Health - Pharmacology - 04.09.2020

Health - Pharmacology - 03.09.2020

Pharmacology - Health - 02.09.2020
Novartis announces NEJM publication of pivotal study of Tabrecta(TM) in patients with METex14 metastatic non-small cell lung cancer
Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exo

Pharmacology - Health - 01.09.2020
Practical guide will support pharmacy staff, and public safety
Practical guide will support pharmacy staff, and public safety
Pharmacists should get more involved in providing guidance to customers purchasing supplements and complementary medicines, a new University of Queensland research paper says.

Pharmacology - Health - 30.08.2020
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 wer

Health - Pharmacology - 28.08.2020
Cambridge to lead national consortium examining immune response to SARS-CoV-2 coronavirus
Cambridge to lead national consortium examining immune response to SARS-CoV-2 coronavirus
The University of Cambridge and Royal Papworth Hospital have secured £1.5million of funding as part of the national effort by UK immunologists to understand immune responses to SARS-CoV-2, the coronavirus that causes COVID-19.

Health - Pharmacology - 28.08.2020
Welsh scientists join UK effort to understand how the immune system responds during Covid-19
Evidence from the pandemic has shown that the immune system can help protect people from Covid-19, but it can also cause damage in severe disease.

Health - Pharmacology - 28.08.2020
University of Birmingham immunologist to lead major UK study to search for answers on COVID-19
The UK Coronavirus Immunology Consortium (UK-CIC) will receive Ā£6.5 million to bring together leading immunologists from 17 research institutions A major new project, led by a University of B

Pharmacology - Health - 27.08.2020
UC San Diego Pharmacist’s Work Helps Save Lives Across the Globe
Jennifer Le, professor in the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego.

Health - Pharmacology - 27.08.2020
Out of Thin Air
With the help of their nurses, the two childhood friends reunited while seeking treatment at UC San Diego Health.

Health - Pharmacology - 26.08.2020
Sex differences in COVID-19 immune responses affect patient outcomes
Sex differences in COVID-19 immune responses affect patient outcomes
Yale researchers have identified significant differences in how the immune systems of women and men respond to the virus that causes COVID-19.

Health - Pharmacology - 26.08.2020
Breakthrough in eliminating dengue, other mosquito-borne diseases
Aedes aegypti mosquitoes carry many viral diseases, including dengue, Zika and yellow fever. They're now invading the U.S. A 27-month trial in Indonesia of a unique method of mosquito control shows that the strategy can reduce the incidence of dengue - a mosquito-borne viral disease of the tropics that threatens nearly half the world's population - by 77%.

Pharmacology - Health - 26.08.2020
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs.

Pharmacology - Health - 26.08.2020
UQ vaccine scientists report positive results from pre-clinical testing
Pre-clinical testing of The University of Queensland's COVID-19 vaccine has produced positive indications about its potential effectiveness and manufacturability.

Pharmacology - Health - 26.08.2020
'The love hormone' - a new treatment for addiction?
’The love hormone’ - a new treatment for addiction?
Even people desperate to end their substance abuse often can't. But thinking differently about how the brain is affected by addiction means the answer could be, ironically, in a pill.

Health - Pharmacology - 25.08.2020
Better drug treatment for miscarriage as patients struggle to access surgery in Covid-19 pandemic
The trial found that the combined drug treatment worked in 83% of cases, compared to 76% in the placebo group - and crucially, it reduced the need for surgery. A new drug combination is more effective for women having miscarriages without symptoms than current standard NHS treatment, according to an NIHR funded study from Tommy's National Centre for Miscarriage Research published today in The Lancet.

Health - Pharmacology - 25.08.2020
U-M spinout Asalyxa Bio developing inflammatory treatment platform, aiding COVID-19 patients
Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at University of Michigan that aims to treat a wide range of inflammatory diseases, has secured seed funding to advance toward the first in-human trials next year.

Pharmacology - Health - 24.08.2020
Mail delays may affect medication supply for nearly 1 in 4 Americans over 50
Data from the National Poll on Healthy Aging show reliance on delivery of medications, often because of insurance requirements The timeliness of mail delivery may affect access to medication for many

Health - Pharmacology - 24.08.2020
Studies neutralizing monoclonal antibodies as possible treatment for COVID-19
The National Institutes of Health (NIH) and Operation Warp Speed have chosen a University of Minnesota School of Public Health research team to begin a global clinical trial of synthetic versions of natural human antibodies - called neutralizing monoclonal antibodies - as a treatment for COVID-19.

Pharmacology - Health - 22.08.2020
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar + Mekinist in advanced melanoma
Phase III COMBI-i trial did not meet primary endpoint for patients with advanced BRAF V600-mutated melanoma Tafinlar + Mekinist remains an effective treatment option based on previously reported larg
1 2 3 4 5 ... 40 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |